Prof Thomas Helleday presents MTHFD2 and other emerging targets such as PKMYT1, MTH1 and Pol Theta at the AACR21 virtual meeting.
One-carbon Therapeutics to Present Trial-in-Progress Poster on ODIN Phase 1/2 Study ofTH9619 at the 2026 ASCO Annual Meeting
Solna, Sweden, May 29th, 2026. One-carbon Therapeutics AB, a clinical-stage
